Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab in dMMR/MSI-H Gastric/GEJ Cancer
NCT05994456Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05994456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05994456.